Schizophrenia

Schizophrenia

Schizophrenia is characterized by three symptom domains and affects ~1% of global population. First and mostly known are the positive symptoms like hallucinations and delusions, secondly are negative symptoms like reduced emotion and lack of motivation and the third symptom domain is cognitive symptoms like a poor memory or disorganized thinking. While there are already many drugs for treating positive symptoms, there is a significant unmet medical need for effective treatments for negative and cognitive symptoms.

Schizophrenia affects approximately 24 million people worldwide. That’s 24 million individual stories and 24 million lives impacted – and that still doesn’t include the countless experiences of the families and carers of those living with this serious mental illness.

The global $1 trillion mental health problem needs more funding

When a patient was diagnosed with schizophrenia, one of his immediate concerns was the stigma he might face: “I will lose the perception of being normal in my community – nobody wants to talk about mental illness. It’s not a fashionable topic.”

Find out more

Improving the current state of schizophrenia care

More than 24 million people worldwide are living with schizophrenia. Despite its global prevalence, schizophrenia is an often misunderstood, serious mental health condition. At Boehringer Ingelheim, we’ve made a long-term, generational commitment to transform the mental health landscape.

Find out more